ダウンロード数: 349
このアイテムのファイル:
| ファイル | 記述 | サイズ | フォーマット | |
|---|---|---|---|---|
| 65_11_469.pdf | 811.69 kB | Adobe PDF | 見る/開く |
| タイトル: | エンザルタミドによる全身倦怠感をCancer fatigue scale(CFS)で評価し眠前投与が有用であった1例 |
| その他のタイトル: | A Case of General Fatigue Caused by Enzalutamide that was Evaluated Using the Cancer Fatigue Scale and Overcome by Switching to Nighttime Treatment |
| 著者: | 芳賀, 一徳  中嶋, 久雄 佐藤, 嘉一 赤樫, 圭吾 新田, 俊一 戸邉, 武蔵 内田, 耕介 本間, 一也 廣部, 恵美 浦濱, 聡 半澤, 辰夫 丹田, 均 |
| 著者名の別形: | Haga, Kazunori Nakajima, Hisao Sato, Yoshikazu Akagashi, Keigo Nitta, Toshikazu Tobe, Musashi Uchida, Kousuke Honma, Ichiya Hirobe, Megumi Urahama, Satoshi Hanzawa, Tatsuo Tanda, Hitoshi |
| キーワード: | Enzalutamide Castration-resistant prostate cancer Cancer Fatigue Scale Nighttime treatment |
| 発行日: | 30-Nov-2019 |
| 出版者: | 泌尿器科紀要刊行会 |
| 誌名: | 泌尿器科紀要 |
| 巻: | 65 |
| 号: | 11 |
| 開始ページ: | 469 |
| 終了ページ: | 472 |
| 抄録: | An 81-year-old man with castration-resistant prostate cancer experienced general fatigue while receiving enzalutamide treatment. In some patients we encountered the enzalutamide treatment had to be interrupted or the dose decreased because of this adverse effect. We evaluated the patient's general fatigue using the Cancer Fatigue Scale (CFS) score and clarified the quantitative information about his general fatigue. In order to maintain the optimal dose, we advised the patient to take enzalutamide at night. This alleviated the adverse effect, and he could maintain the optimal dose of this medicine. We compared the CFS score before and after switching to nighttime treatment and found improvement. This is the first report of a CFS-based evaluation of the improvement in general fatigue caused by enzalutamide by switching to nighttime treatment. |
| 著作権等: | 許諾条件により本文は2020/12/01に公開 |
| DOI: | 10.14989/ActaUrolJap_65_11_469 |
| URI: | http://hdl.handle.net/2433/245257 |
| PubMed ID: | 31902181 |
| 出現コレクション: | Vol.65 No.11 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。